Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies
SC Pitts, J Schlom, RN Donahue - Journal of Experimental & Clinical …, 2024 - Springer
Longitudinal sampling of tumor tissue from patients with solid cancers, aside from melanoma
and a few other cases, is often unfeasible, and thus may not capture the plasticity of …
and a few other cases, is often unfeasible, and thus may not capture the plasticity of …
Soluble PD‐L1 predicts tumor response and immune‐related adverse events in patients with advanced melanoma treated with anti–PD‐1 antibodies
K Oya, Y Nakamura, LTW Shen… - The Journal of …, 2024 - Wiley Online Library
Immune checkpoint inhibitors (ICIs) bring prognostic benefits to patients with malignancies.
However, there is a substantial number of patients whose lesions are not improved by ICIs …
However, there is a substantial number of patients whose lesions are not improved by ICIs …
Serum sPD1 and sPDL1 as Biomarkers for Evaluating the Immune State of Lung Adenocarcinoma Patients
Y Wu, H Guo, J Yue, P Xu - Journal of Immunology Research, 2022 - Wiley Online Library
A large proportion of cancer patients benefit from immune checkpoint therapy, while few
studies focused on the relationship between soluble PD1 (sPD1) and soluble PDL1 (sPDL1) …
studies focused on the relationship between soluble PD1 (sPD1) and soluble PDL1 (sPDL1) …
Растворимые молекулы иммунных контрольных точек: механизмы образования, функции, роль при злокачественных новообразованиях (Обзор литературы)
ТВ Глазанова, ИЕ Павлова, ЕВ Кузьмич… - Медицинская …, 2024 - mimmun.ru
Аннотация Иммунные контрольные точки (ИКТ) представляют собой обширный и
разнообразный комплекс стимулирующих и ингибирующих сигнальных путей, которые …
разнообразный комплекс стимулирующих и ингибирующих сигнальных путей, которые …